These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 38691321)

  • 1. Competing Benefits and Competing Hazards: The Benefit to Harm Balance in Individual Patients in Rational Therapeutics.
    Ferner RE; Aronson JK
    Drug Saf; 2024 Aug; 47(8):721-731. PubMed ID: 38691321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Determining the harm-benefit balance of an intervention: for each patient.
    Prescrire Int; 2014 Nov; 23(154):274-7. PubMed ID: 25954801
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Methodologies for pragmatic and efficient assessment of benefits and harms: Application to the SOCRATES trial.
    Evans SR; Knutsson M; Amarenco P; Albers GW; Bath PM; Denison H; Ladenvall P; Jonasson J; Easton JD; Minematsu K; Molina CA; Wang Y; Wong KL; Johnston SC
    Clin Trials; 2020 Dec; 17(6):617-626. PubMed ID: 32666831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GLP-1 receptor agonists for weight reduction in people living with obesity but without diabetes: a living benefit-harm modelling study.
    Moll H; Frey E; Gerber P; Geidl B; Kaufmann M; Braun J; Beuschlein F; Puhan MA; Yebyo HG
    EClinicalMedicine; 2024 Jul; 73():102661. PubMed ID: 38846069
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Benefit-harm analysis and charts for individualized and preference-sensitive prevention: example of low dose aspirin for primary prevention of cardiovascular disease and cancer.
    Puhan MA; Yu T; Stegeman I; Varadhan R; Singh S; Boyd CM
    BMC Med; 2015 Oct; 13():250. PubMed ID: 26423305
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Harms from medicines: inevitable, in error or intentional.
    Ferner RE
    Br J Clin Pharmacol; 2014 Mar; 77(3):403-9. PubMed ID: 23683079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The implications of competing risks and direct treatment disutility in cardiovascular disease and osteoporotic fracture: risk prediction and cost effectiveness analysis.
    Guthrie B; Rogers G; Livingstone S; Morales DR; Donnan P; Davis S; Youn JH; Hainsworth R; Thompson A; Payne K
    Health Soc Care Deliv Res; 2024 Feb; 12(4):1-275. PubMed ID: 38420962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Minderoo-Monaco Commission on Plastics and Human Health.
    Landrigan PJ; Raps H; Cropper M; Bald C; Brunner M; Canonizado EM; Charles D; Chiles TC; Donohue MJ; Enck J; Fenichel P; Fleming LE; Ferrier-Pages C; Fordham R; Gozt A; Griffin C; Hahn ME; Haryanto B; Hixson R; Ianelli H; James BD; Kumar P; Laborde A; Law KL; Martin K; Mu J; Mulders Y; Mustapha A; Niu J; Pahl S; Park Y; Pedrotti ML; Pitt JA; Ruchirawat M; Seewoo BJ; Spring M; Stegeman JJ; Suk W; Symeonides C; Takada H; Thompson RC; Vicini A; Wang Z; Whitman E; Wirth D; Wolff M; Yousuf AK; Dunlop S
    Ann Glob Health; 2023; 89(1):23. PubMed ID: 36969097
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinicians' perceptions of the benefits and harms of prostate and colorectal cancer screening.
    Elstad EA; Sutkowi-Hemstreet A; Sheridan SL; Vu M; Harris R; Reyna VF; Rini C; Earp JA; Brewer NT
    Med Decis Making; 2015 May; 35(4):467-76. PubMed ID: 25637592
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PCSK9 inhibitors and ezetimibe for the reduction of cardiovascular events: a clinical practice guideline with risk-stratified recommendations.
    Hao Q; Aertgeerts B; Guyatt G; Bekkering GE; Vandvik PO; Khan SU; Rodondi N; Jackson R; Reny JL; Al Ansary L; Van Driel M; Assendelft WJJ; Agoritsas T; Spencer F; Siemieniuk RAC; Lytvyn L; Heen AF; Zhao Q; Riaz IB; Ramaekers D; Okwen PM; Zhu Y; Dawson A; Ovidiu MC; Vanbrabant W; Li S; Delvaux N
    BMJ; 2022 May; 377():e069066. PubMed ID: 35508320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Balance of benefits and harms of different blood pressure targets in people with multiple chronic conditions: a quantitative benefit-harm assessment.
    Aschmann HE; Boyd CM; Robbins CW; Mularski RA; Chan WV; Sheehan OC; Wilson RF; Bennett WL; Bayliss EA; Yu T; Leff B; Armacost K; Glover C; Maslow K; Mintz S; Puhan MA
    BMJ Open; 2019 Aug; 9(8):e028438. PubMed ID: 31471435
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Using benefit harm tradeoffs to estimate sufficiently important difference: the case of the common cold.
    Barrett B; Brown R; Mundt M; Dye L; Alt J; Safdar N; Maberry R
    Med Decis Making; 2005; 25(1):47-55. PubMed ID: 15673581
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preventing harm in resuscitation medicine.
    Ardagh M
    N Z Med J; 1997 Apr; 110(1041):113-5. PubMed ID: 9140410
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Global variation of risk thresholds for initiating statins for primary prevention of cardiovascular disease: a benefit-harm balance modelling study.
    Yebyo HG; Zappacosta S; Aschmann HE; Haile SR; Puhan MA
    BMC Cardiovasc Disord; 2020 Sep; 20(1):418. PubMed ID: 32942999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement.
    ; Grossman DC; Curry SJ; Owens DK; Bibbins-Domingo K; Caughey AB; Davidson KW; Doubeni CA; Ebell M; Epling JW; Kemper AR; Krist AH; Kubik M; Landefeld CS; Mangione CM; Silverstein M; Simon MA; Siu AL; Tseng CW
    JAMA; 2018 May; 319(18):1901-1913. PubMed ID: 29801017
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Public Health Interventions with Harms and Benefits: A Graphical Framework for Evaluating Tradeoffs.
    Pitt AL; Goldhaber-Fiebert JD; Brandeau ML
    Med Decis Making; 2020 Nov; 40(8):978-989. PubMed ID: 32996356
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patients' expectations of the benefits and harms of treatments, screening, and tests: a systematic review.
    Hoffmann TC; Del Mar C
    JAMA Intern Med; 2015 Feb; 175(2):274-86. PubMed ID: 25531451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinicians' Expectations of the Benefits and Harms of Treatments, Screening, and Tests: A Systematic Review.
    Hoffmann TC; Del Mar C
    JAMA Intern Med; 2017 Mar; 177(3):407-419. PubMed ID: 28097303
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.